ClinicalTrials.gg
CompletedNCT01982240Updated Dec 26, 2019Results posted

12-Week Study of Plecanatide for CIC (The CIC3 Study)

A Phase 3 interventional study of Plecanatide and Placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 189 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-26.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,394
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
3rd of 12
1,394 · median 800
Started
2013
with 1 other
Phase 3
6 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 5th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.

Read the detailed description

This is a randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States (US) and Canada. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation.

There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered.

03

Conditions studied

  • Chronic Idiopathic Constipation

Browse trials for

Keywords

  • CIC
  • Constipation
  • Chronic Constipation
  • Synergy
  • Plecanatide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-80, inclusive
  • Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months
  • Completed a colonoscopy in accordance with AGA colon cancer screening guidelines (5 years), with no findings
  • Willing to maintain a stable diet during the study

Exclusion criteria

Exclusion Criteria:

  • Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment
  • Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable
  • History of cathartic colon, laxative, enema abuse, or ischemic colitis
  • Fecal impaction within 3 months of screening
  • Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
  • Unexplained and "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis
  • Major surgery, stroke or MI within 60 days of screening
  • Participated in a previous plecanatide clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,394 participants (actual)

Study arms

  • Active comparator
    Plecanatide 3.0 mg

    Plecanatide tablets 3.0 mg QD for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Plecanatide 6.0 mg

    Plecanatide tablets 6.0 mg QD for 12 weeks

    Drug: Plecanatide

  • Placebo comparator
    Placebo

    Matching placebo tablets QD for 12 weeks

    Drug: Placebo

  • Other
    Bisacodyl

    Rescue medication

    Drug: Bisacodyl

Interventions

  • Plecanatide tablets QD for 12 weeks

    Also known as: Trulance

  • DrugPlacebo

    Matching placebo tablets QD for 12 weeks

    Also known as: Trulance placebo

  • Rescue medication

    Also known as: Dulcolax

06

What researchers measure

Primary outcomes

  1. Number of Durable Overall CSBM Responders , Mean Replacement Approach

    A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, included at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

    Time frame: 12-week Treatment Period

Secondary outcomes

  1. Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach

    A Complete Spontaneous Bowel Movement (CSBM) was a Bowel Movement (BM) that occurred in the absence of laxative use within 24 hours of the BM and the patient reported a feeling of complete evacuation. A weekly responder had 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week.

    Time frame: 12-Week Treatment Period

  2. Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach

    The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was assessed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period in the BM and Symptom Diary.

    Time frame: 12-Week Treatment Period

  3. Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach

    The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

    Time frame: 12-Week Treatment Period

  4. Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach

    Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

    Time frame: 12-Week Treatment Period

07

Results

Posted Mar 21, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboPlecanatide 3.0 mgPlecanatide 6 mg
Started452453441
Completed385384371
Not completed676970

Outcome measures

PrimaryNumber of Durable Overall CSBM Responders , Mean Replacement Approach

A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, included at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

Time frame:
12-week Treatment Period
Reported as:
Count of participants · Participants
Number of Durable Overall CSBM Responders , Mean Replacement Approach
ParticipantsPlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
Number of Durable Overall CSBM Responders , Mean Replacement Approach469586
SecondaryChange From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach

A Complete Spontaneous Bowel Movement (CSBM) was a Bowel Movement (BM) that occurred in the absence of laxative use within 24 hours of the BM and the patient reported a feeling of complete evacuation. A weekly responder had 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week.

Time frame:
12-Week Treatment Period
Reported as:
Mean · CSBMs per week
Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach
CSBMs per weekPlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
Baseline0.39 ± 0.5700.32 ± 0.5140.32 ± 0.509
Week 12 change from baseline1.45 ± 2.3102.68 ± 3.8912.39 ± 3.296
SecondaryChange From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach

The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was assessed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period in the BM and Symptom Diary.

Time frame:
12-Week Treatment Period
Reported as:
Mean · SBMs per week
Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach
SBMs per weekPlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
Baseline2.18 ± 2.0321.97 ± 1.7721.82 ± 1.824
Week 12 change from baseline1.37 ± 2.8813.30 ± 4.6283.24 ± 4.518
SecondaryChange From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach

The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

Time frame:
12-Week Treatment Period
Reported as:
Mean · score on a scale
Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach
score on a scalePlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
Baseline2.56 ± 1.1142.52 ± 1.0462.59 ± 1.171
Week 12 change from baseline0.83 ± 1.2461.56 ± 1.5041.47 ± 1.584
SecondaryChange From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach

Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

Time frame:
12-Week Treatment Period
Reported as:
Mean · score on a scale
Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach
score on a scalePlecanatide 3.0 mgPlaceboPlecanatide 6.0 mg
Baseline2.31 ± 0.8352.30 ± 0.8422.28 ± 0.894
Week 12 change from baseline-0.70 ± 0.967-0.95 ± 1.027-1.00 ± 1.155

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—4/458 (0.9%)8/458 (1.7%)
Plecanatide 3.0 mg—6/474 (1.3%)38/474 (8%)
Plecanatide 6.0 mg—5/457 (1.1%)37/457 (8.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
PregnancyPregnancy, puerperium and perinatal conditions0/4582/4740/457
Intestinal obstructionGastrointestinal disorders0/4581/4741/457
GastroenteritisInfections and infestations0/4580/4741/457
Staphylococcal infectionInfections and infestations0/4580/4741/457
Ankle fractureInjury, poisoning and procedural complications0/4580/4741/457
HeadacheNervous system disorders0/4580/4741/457
DiverticulitisInfections and infestations1/4580/4740/457
MastitisInfections and infestations1/4580/4740/457
PneumoniaInfections and infestations1/4580/4740/457
Peripheral arterial occlusive diseaseVascular disorders1/4580/4740/457
Most frequent other events
Most frequent other events
EventPlaceboPlecanatide 3.0 mgPlecanatide 6.0 mg
DiarrhoeaGastrointestinal disorders6/45828/47426/457
NasopharyngitisInfections and infestations0/4580/47411/457
SinusitisInfections and infestations2/45810/4740/457

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPlecanatide 3.0 mgPlecanatide 6.0 mgTotal
Mean46.4 (18 to 78)45.0 (18 to 79)45.1 (18 to 79)45.5 (18 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPlecanatide 3.0 mgPlecanatide 6.0 mgTotal
Female3573683621087
Male958579259
08

Study locations

189 sites
  • Synergy Research Site
    Birmingham, Alabama 35242, United States
  • Synergy Research Site
    Dothan, Alabama 36305, United States
  • Synergy Research Site
    Gulf Shores, Alabama 36542, United States
  • Synergy Research Site
    Huntsville, Alabama 35801, United States
  • Synergy Research Site
    Mobile, Alabama 36695, United States
  • Synergy Research Site
    Mesa, Arizona 85206, United States
  • Synergy Research Site
    Phoenix, Arizona 85018, United States
  • Synergy Research Site
    Phoenix, Arizona 85023, United States
  • Synergy Research Site
    Tempe, Arizona 85283, United States
  • Synergy Research Site
    Tucson, Arizona 85712, United States
  • Synergy Research Site
    Hot Springs, Arkansas 71913, United States
  • Synergy Research Site
    Little Rock, Arkansas 72211, United States
  • Synergy Research Site
    North Little Rock, Arkansas 72117, United States
  • Synergy Research Site
    Anaheim, California 92801, United States
  • Synergy Research Site
    Anaheim, California 92804, United States
  • Synergy Research Site
    Carlsbad, California 92008, United States
  • Synergy Research Site
    Cerritos, California 90703, United States
  • Synergy Research Site
    Chula Vista, California 91910, United States
  • Synergy Research Site
    El Cajon, California 92020, United States
  • Synergy Research Site
    Encinitas, California 92024, United States
  • Synergy Research Site
    Encino, California 91436, United States
  • Synergy Research Site
    Fountain Valley, California 92708, United States
  • Synergy Research Site
    Fresno, California 93726, United States
  • Synergy Research Site
    Hawaiian Gardens, California 90716, United States
  • Synergy Research Site
    Lancaster, California 93534, United States
  • Synergy Research Site
    Long Beach, California 90806, United States
  • Synergy Research Site
    Los Angeles, California 90015, United States
  • Synergy Research Site
    Los Angeles, California 90045, United States
  • Synergy Research Site
    Los Angeles, California 90067, United States
  • Synergy Research Site
    Mission Hills, California 91345, United States
  • Synergy Research Site
    Murrieta, California 92562, United States
  • Synergy Research Site
    North Hollywood, California 91606, United States
  • Synergy Research Site
    Oceanside, California 92054, United States
  • Synergy Research Site
    Oxnard, California 93030, United States
  • Synergy Research Site
    Pasadena, California 91105, United States
  • Synergy Research Site
    Poway, California 92064, United States
  • Synergy Research Site
    Sacramento, California 95816, United States
  • Synergy Research Site
    San Diego, California 92101, United States
  • Synergy Research Site
    San Diego, California 92103, United States
  • Synergy Research Site
    San Diego, California 92108, United States
  • Synergy Research Site
    San Diego, California 92114, United States
  • Synergy Research Site
    Thousand Oaks, California 91360, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80907, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80909, United States
  • Synergy Research Site
    Denver, Colorado 80218, United States
  • Synergy Research Site
    Denver, Colorado 80220, United States
  • Synergy Research Site
    Denver, Colorado 80246, United States
  • Synergy Research Site
    Littleton, Colorado 80120, United States
  • Synergy Research Site
    Bristol, Connecticut 06010, United States
  • Synergy Research Site
    Danbury, Connecticut 06810, United States
  • Synergy Research Site
    Waterbury, Connecticut 06708, United States
  • Synergy Research Site
    Boynton Beach, Florida 33426, United States
  • Synergy Research Site
    Clearwater, Florida 33759, United States
  • Synergy Research Site
    DeLand, Florida 32720, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33306, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33308, United States
  • Synergy Research Site
    Hialeah, Florida 33012, United States
  • Synergy Research Site
    Jupiter, Florida 33458, United States
  • Synergy Research Site
    Lakeland, Florida 33805, United States
  • Synergy Research Site
    Lynn Haven, Florida 32444, United States
  • Synergy Research Site
    Miami, Florida 33130, United States
  • Synergy Research Site
    Miami, Florida 33165, United States
  • Synergy Research Site
    Miami, Florida 33173, United States
  • Synergy Research Site
    Miami, Florida 33174, United States
  • Synergy Research Site
    Miami, Florida 33185, United States
  • Synergy Research Site
    Miami, Florida 33186, United States
  • Synergy Research Site
    Orlando, Florida 32803, United States
  • Synergy Research Site
    Orlando, Florida 32806, United States
  • Synergy Research Site
    Port Orange, Florida 32129, United States
  • Synergy Research Site
    Tampa, Florida 33604, United States
  • Synergy Research Site
    Tampa, Florida 33606, United States
  • Synergy Research Site
    Tampa, Florida 33617, United States
  • Synergy Research Site
    Athens, Georgia 30606, United States
  • Synergy Research Site
    Augusta, Georgia 30912, United States
  • Synergy Research Site
    Decatur, Georgia 30032, United States
  • Synergy Research Site
    Decatur, Georgia 30033, United States
  • Synergy Research Site
    Johns Creek, Georgia 30097, United States
  • Synergy Research Site
    Oakwood, Georgia 30566, United States
  • Synergy Research Site
    Savannah, Georgia 31406, United States
  • Synergy Research Site
    Smyrna, Georgia 30082, United States
  • Synergy Research Site
    Evanston, Illinois 60201, United States
  • Synergy Research Site
    Clive, Iowa 50325, United States
  • Synergy Research Site
    Augusta, Kansas 67010, United States
  • Synergy Research Site
    Newton, Kansas 67114, United States
  • Synergy Research Site
    Shawnee Mission, Kansas 66218, United States
  • Synergy Research Site
    Wichita, Kansas 67205, United States
  • Synergy Research Site
    Wichita, Kansas 67207, United States
  • Synergy Research Site
    Lexington, Kentucky 40503, United States
  • Synergy Research Site
    Lexington, Kentucky 40504, United States
  • Synergy Research Site
    Bastrop, Louisiana 71220, United States
  • Synergy Research Site
    Marrero, Louisiana 70072, United States
  • Synergy Research Site
    Metairie, Louisiana 70006, United States
  • Synergy Research Site
    New Orleans, Louisiana 70115, United States
  • Synergy Research Site
    New Orleans, Louisiana 70119, United States
  • Synergy Research Site
    Shreveport, Louisiana 71103, United States
  • Synergy Research Site
    Chevy Chase, Maryland 20815, United States
  • Synergy Research Site
    Boston, Massachusetts 02131, United States
  • Synergy Research Site
    Brockton, Massachusetts 02302, United States
  • Synergy Research Site
    New Bedford, Massachusetts 02740, United States
  • Synergy Research Site
    Chesterfield, Michigan 48047, United States

Showing the first 100 of 189 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moshiree B, Schoenfeld P, Franklin H, Rezaie A. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. Clin Ther. 2022 Jan;44(1):98-110.e1. doi: 10.1016/j.clinthera.2021.11.009. Epub 2022 Jan 25. PubMed 35086735 ↗
  • Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10. PubMed 32660770 ↗
  • Miner PB Jr, Koltun WD, Wiener GJ, De La Portilla M, Prieto B, Shailubhai K, Layton MB, Barrow L, Magnus L, Griffin PH. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. Am J Gastroenterol. 2017 Apr;112(4):613-621. doi: 10.1038/ajg.2016.611. Epub 2017 Feb 7. PubMed 28169285 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 3 years 11 months after primary completion. A results delay was requested in Apr 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 13, 2013
Start
Nov 2013
Primary completionActual
Apr 2015
CompletionActual
Jun 2015
Results delay requested
Apr 26, 2016
Results first posted
Mar 21, 2019
Last update
Dec 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01982240
Responsible party
Sponsor
First posted
Nov 13, 2013
Start date
Nov 2013
Primary completion
Apr 2015
Completion
Jun 2015
Results posted
Mar 21, 2019
Last update
Dec 26, 2019

Study contacts

Mary Beth Layton
study director · Synergy Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Plecanatide · Bisacodyl

Start the discussion